Phage Based Diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Menu
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us

PBD Biotech gains attention of East of England Investment Catalyst among other investors

TB in humans and animals is a huge global problem as there is a lack of rapid, accurate ways to detect the disease at an early stage. PBD Biotech has developed Actiphage®, a new sensitive test that can detect the presence of the pathogen, mycobacteria, at a very early stage within a few hours. This creates the opportunity for new ways to treat or manage this devastating disease.
  • October 7, 2019
  • Company
  • investment
Actiphage

Gaining funding to support further trials of Actiphage and to set up new laboratories in Suffolk is a priority for this growing international company. Reaching the next round of the East of England Investment Catalyst is therefore an exciting development.

PBD Biotech CEO, Mark Hammond, comments: “We are actively fundraising at the moment and the international market potential of Actiphage is attracting significant interest. However, our roots are in Suffolk and we intend to stay and grow here so gaining support from the team behind the East of England Investment Catalyst is important to us.”

PBD Bitoech is part of the final cohort for the inaugural Investment Catalyst programme, joining ten other firms from across East Anglia. Linn Clabburn, programme director of the Cambridge Norwich Tech Corridor, which has organised the Investment Catalyst, said: “There were some fantastic applications for the East of England Investment Catalyst, so shortlisting was not an easy task.

“We believe these eleven companies embody the best the region’s business scene has to offer, and look forward to working with them over the coming weeks.”

Award-winning PBD Biotech has secured European and American patents, and its Actiphage test can be used in England under the Department for Environment’s Exceptional Private Use protocol for cattle herds chronically infected with TB. The Animal Health Laboratory within the Colorado Department of Agriculture is also currently trialling Actiphage.

Following multiple successful proof of concept studies, the firm is now looking for funding and partnerships to proceed with validation of the technology.

Mark continues: “PBD Biotech is establishing a growing reputation as a global leader in mycobacterial diagnostics, and is building a community of individuals and organisations with a commitment to overcoming bovine TB, human TB and Johne’s disease and would encourage anyone with an interest to get in touch.”

Share:

Related posts

Loading...
Blood test

International demand for first sensitive test for mycobacteria in blood or milk

August 15, 2018
Bovine TB is one of a group of diseases caused by mycobacteria that has devastated the agricultural industry worldwide. Now UK agri-tech start-up PBD Biotech, developers of the first rapid test for live mycobacteria, has secured £400,000 in its first...
Blood test

International demand for first sensitive test for mycobacteria in blood or milk

August 15, 2018
Bovine TB is one of a group of diseases caused by mycobacteria that has devastated the agricultural industry worldwide. Now...
Dr Berwyn Clarke at REAP

‘Angel investors bring more than money’ – Interview with PBD Biotech CEO

August 7, 2018
Following PBD Biotech’s successful seed funding round, CEO Dr Berwyn Clarke spoke to Growth Business, the leading media portal for entrepreneurs, about the start-up’s strategic approach to securing the right investment for phage-based technology.
Dr Berwyn Clarke at REAP

‘Angel investors bring more than money’ – Interview with PBD Biotech CEO

August 7, 2018
Following PBD Biotech’s successful seed funding round, CEO Dr Berwyn Clarke spoke to Growth Business, the leading media portal for...
New Anglia LEP CEO Chris Starkie and PBD Biotech CEO Berwyn Clarke

PBD Biotech gains funding to fuel overseas expansion

June 27, 2018
To meet the growing international demand for its rapid, sensitive test for mycobacterial disease, PBD Biotech is to establish a Canadian subsidiary in Saskatoon to support its first overseas commercial activity.
New Anglia LEP CEO Chris Starkie and PBD Biotech CEO Berwyn Clarke

PBD Biotech gains funding to fuel overseas expansion

June 27, 2018
To meet the growing international demand for its rapid, sensitive test for mycobacterial disease, PBD Biotech is to establish a...
Eastern Agri-Tech Innovation Fund

PBD Biotech award grant to support rapid, accurate, diagnosis of bacterial infection in animals

June 7, 2017
PBD Biotech Ltd has received a grant of £60,000 from the Greater Cambridge Greater Peterborough LEP’s Eastern Agri-Tech Growth Initiative to support its innovative technology for rapid, accurate and sensitive diagnosis of bacterial infection in animals.
Eastern Agri-Tech Innovation Fund

PBD Biotech award grant to support rapid, accurate, diagnosis of bacterial infection in animals

June 7, 2017
PBD Biotech Ltd has received a grant of £60,000 from the Greater Cambridge Greater Peterborough LEP’s Eastern Agri-Tech Growth Initiative...

developers of phage-based diagnostics

Contact Us

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!
PBD Biotech

More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB

Read More
PBD Biotech

Delighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies

Read More
PBD Biotech

Testing 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease

Read More